Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

Overuse of inhalers can increase heart attack risk

Overuse of reliever inhalers is associated with higher risks of developing and dying from...

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Content from other channels on our network

Sparc and Levidian partner on UAE graphene‍-‍based coatings manufacturing

The roles of the vendor and EPCs in the project bidding process

ARC awards $82.5m for new research hubs and training centres

Industrial electricity costs could halve by sharing infrastructure

Seeq and Applied Computing partner on industrial AI for energy operations

AI and robotic advances to be showcased at APPEX 2027

AFGC welcomes Domestic Gas Reservation Bill

Beverage facility built to keep the good times rolling

Industries transitioning away from gas, A2EP report released

Six on the shelf: from frozen treats to smoothies & meal kits

A Day in the Life of a rural generalist anaesthetist and men's mental health advocate

Government to commission aged care assessment tool review

Services commence today at Flinders Street Health

Burnout in health care isn't an 80/20 problem: why a more balanced view is needed and what it means for you and your workplace

A Good Cleaning Schedule: Best Practices for Healthcare Facilities